JAK1 Inhibitor From Galapagos Headed To Phase III – With Or Without AbbVie
This article was originally published in The Pink Sheet Daily
Executive Summary
Filgotinib posts promising interim Phase IIb results in rheumatoid arthritis; although more results are to come. AbbVie seems likely to opt in later this year on the potential successor to Humira.